In a significant development, CytomX Therapeutics recently announced the initiation of a Good Laboratory Practice (GLP) toxicology study for its first clinical candidate in the PROBODYT-Cell Engaging Bispecific (TCB) collaboration with Astellas. This momentous milestone has triggered a remarkable $5 million milestone payment from Astellas to CytomX. This article aims to outline the key facts surrounding this achievement and assess its potential impact on CytomX Therapeutics as a leading biotechnology company.
Milestone Achievement in PROBODYT-Cell Engaging Bispecific Collaboration Amplifies CytomX Therapeutics’ Positive Prospects
Published |
Modified
CSIMarket Newsroom | CSIMarket.com
CSIMarket Newsroom | CSIMarket.com
Source for this article: Based on Cytomx Therapeutics Inc ’s official statement
For details on how CSIMarket validates financial and corporate news, please review our
Editorial Standards & Fact-Checking Policy
.
Comments